Friday, 11 May 2012

Eurax


Generic Name: Crotamiton
Class: Scabicides and Pediculicides
VA Class: AP900
Chemical Name: N-ethyl-N-(o-methylphenyl)-2-butenamide
CAS Number: 483-63-6

Introduction

Scabicide and antipruritic agent.115


Uses for Eurax


Scabies


Alternative for topical treatment of scabies in adults.103 107 115 120 AAP, CDC, and others usually recommend topical permethrin 5% as scabicide of choice;103 104 105 107 111 116 120 122 oral ivermectin also recommended by CDC as a drug of choice.104


May be less effective than topical permethrin.105 118 121 122 Treatment failures have occurred;103 109 118 several applications of the drug may be necessary.105 109


Other scabicides usually recommended for treatment of severe or crusted (Norwegian) scabies†.102 103 104 109 113 Aggressive treatment with a multiple-dose oral ivermectin regimen or concomitant use of oral ivermectin and a topical scabicide may be necessary.103 104 HIV-infected and other immunocompromised patients are at increased risk of developing Norwegian scabies; CDC recommends that such patients be managed in consultation with an expert.104


HIV-infected individuals with uncomplicated scabies should receive the same treatment regimens as those without HIV infection.104


Pediculosis


Has been used for treatment of pediculosis capitis† (head lice infestation).103 Safety and efficacy not established.103


Treatment of pediculosis corporis† (body lice infestation).103 One of several options recommended for treatment of pediculosis corporis in the adjunctive treatment of epidemic (louse-borne) typhus.103 The causative agent of epidemic typhus (Rickettsia prowazekii) is transmitted person-to-person by Pediculus humanus corporis and thorough delousing (especially among exposed contacts of individuals with typhus) is recommended in epidemic situations.103


Pruritus


Symptomatic treatment of pruritus.115


Eurax Dosage and Administration


General


Measures to Avoid Reinfestation and Transmission



  • To avoid reinfestation or transmission of scabies, clothing and bed linen that may have been contaminated by the infested individual during the 3 days prior to treatment should be decontaminated (machine-washed in hot water and dried in a hot dryer or dry-cleaned).103 104




  • Items that cannot be laundered or dry-cleaned should be removed from body contact for ≥72 hours.103




  • Fumigation of living areas is not necessary and is not recommended.103 104



Administration


Topical Administration


Apply topically to skin as 10% cream or lotion.115


Do not apply to face, eyes, mouth,115 urethral meatus, or mucous membranes.a For external use only; do not administer orally or intravaginally.115


Shake lotion before using.115


Scabies

Before applying crotamiton for the treatment of scabies, the patient should bathe or shower with soap and water,115 taking care to scrub and remove scaling or crusted detritus, then towel dry.a


Apply thin layer of the cream or lotion uniformly and massage thoroughly into all skin surfaces below the chin (particularly all creases and folds) including the entire trunk and extremities from the neck to the toes (including the soles of the feet).115 Trim fingernails short and apply the cream or lotion underneath the fingernails with a toothbrush; wrap the toothbrush in paper and properly discard to prevent potential oral crotamiton exposure and toxicity.115


Remove the cream or lotion 48 hours after the last application by bathing.103 115


Sexual contacts of patients receiving treatment for scabies and other individuals (household, family) who have had close personal contact with the patient within the previous month should be examined and treated.104


The CDC recommends that scabies epidemics in institutional settings (e.g., nursing homes, hospitals, residential facilities and communities) be managed in consultation with an expert.104 The entire population at risk should be treated during institutional outbreaks.104 119


Pruritus does not indicate treatment failure and is not usually considered an indication for retreatment;103 such pruritus results from a hypersensitivity reaction of the host to the mite103 104 and may persist for several weeks despite successful treatment.103 Oral antihistamines and/or topical corticosteroids may be used to help relieve pruritus.103 Topical or oral anti-infectives are indicated for treatment of secondary bacterial infections of excoriated skin lesions.103


Dosage


Pediatric Patients


Scabies†

Topical

Cream or lotion: Apply a thin, uniform layer and massage thoroughly into all skin surfaces below the chin (particularly to all creases and folds) including the entire trunk and extremities from the neck to the toes (including the soles of the feet and underneath the fingernails).115 A proportionately smaller amount is applied in children compared to the amount applied in adults (30 g usually is sufficient in adults).a Wash off by bathing 48 hours after the last application.115


The manufacturer recommends a second application 24 hours after the first treatment.115 Frequent treatment failures reported;103 109 some clinicians suggest several applications are necessary to cure scabies.105 109 CDC recommends that patients who do not respond to crotamiton should be retreated with an alternative regimen.104


Pediculosis†

Pediculosis Capitis† (Head Lice Infestation)

Topical

Lotion has been applied to the scalp and left on for 24 hours before being washed off.103


Adults


Scabies

Topical

Cream or lotion: Apply a thin, uniform layer and massage thoroughly into all skin surfaces below the chin (particularly to all creases and folds) including the entire trunk and extremities from the neck to the toes (including the soles of the feet and underneath the fingernails).115 Usually, 30 g of the cream is sufficient for one application.115 Wash off by bathing 48 hours after the last application.115


The manufacturer recommends a second application 24 hours after the first treatment.115 Frequent treatment failures reported;103 109 some clinicians suggest several applications are necessary to cure scabies.105 109 CDC recommends retreating patients who do not respond to crotamiton with an alternative regimen.104


Pediculosis†

Pediculosis Capitis† (Head Lice Infestation)

Topical

Lotion has been applied to the scalp and left on for 24 hours before being washed off.103


Pruritus

Topical

Cream or lotion: Massage gently into affected areas until completely absorbed; repeat application as needed.115


Cautions for Eurax


Contraindications



  • Known sensitivity or allergy to crotamiton or known primary irritation response to other topical medications.115



Warnings/Precautions


Sensitivity Reactions


Dermatologic and Sensitivity Reactions

If severe irritation or a sensitivity reaction occurs following topical application, discontinue and initiate appropriate therapy.115


General Precautions


Administration Precautions

Avoid contact with the eyes or mouth since irritation may occur.115


Avoid contact with mucous membranes, the vagina, and urethral meatus.a 115


Do not apply to acutely inflamed skin or denuded or weeping skin surfaces until acute inflammation has resolved.115


Specific Populations


Pregnancy

Category C.115


Lactation

Information regarding distribution into milk not available.115


Pediatric Use

Safety and efficacy not established in children.115


Geriatric Use

Insufficient experience in controlled clinical studies in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.115 Other clinical experience has not revealed age-related differences in response; however, greater sensitivity of some geriatric individuals cannot be ruled out.115


Common Adverse Effects


Primary irritation reactions (e.g., dermatitis, pruritus, rash), allergic sensitivity reactions.115


Eurax Pharmacokinetics


Absorption


Bioavailability


Absorbed systemically following topical application to skin.117


Elimination


Elimination Route


In a study in healthy adults using radiolabeled crotamiton 10% lotion applied topically twice daily (0.229 mL applied on an area of the forearm 229 cm2), 4.8–8.8% of the dose (measured as radioactivity) was eliminated in urine.117


Half-life


Following topical application to skin, absorption half-life is 2.7 hours and rate of elimination is 30.9 hours.117


Stability


Storage


Topical


Cream or Lotion

Room temperature.115


Actions and SpectrumActions



  • The mechanisms of crotamiton’s scabicidal,115 pediculicidal,103 and antipruritic effects 115 not known.




  • Active against Sarcoptes scabiei (mite that causes scabies),103 104 115 Pediculus humanus var. capitis (head louse),103 and Pediculus humanus var. corporis (body louse).103




  • Resistance to crotamiton has not been conclusively demonstrated in S. scabiei.a



Advice to Patients



  • Importance of using only as directed.115




  • Advise patients regarding personal protective measures to avoid reinfestation or transmission of scabies.103 104 115




  • Importance of taking a routine bath or shower prior to application, applying the cream or lotion as directed, and removing the drug by bathing 48 hours after the last application.115




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription or OTC drugs, dietary supplements, herbal supplements, or any other skin product.115




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.115




  • Importance of informing patients of other important precautionary information.115 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


















Crotamiton

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Topical



Cream



10%



Eurax (with propylene glycol)



Bristol-Myers Squibb



Lotion



10%



Eurax (with propylene glycol)



Bristol-Myers Squibb



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References


Only references cited for selected revisions after 1984 are available electronically.



102. Estes SA, Estes J. Therapy of scabies: nursing homes, hospitals, and the homeless. Semin Dermatol. 1993; 12:26-33. [PubMed 7682834]



103. American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.



104. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Recomm Rep. 2006; 55(RR-11):1-94.



105. Anon. Permethrin for scabies. Med Lett Drugs Ther. 1990; 32:21-2. [PubMed 2179695]



107. Anon. Drugs for parasitic infections. Med Lett Drugs Ther. Aug 2004. From the Medical Letter web site ()



108. Rico MJ, Myers SA, Sanchez MR et al. Guidelines of care for dermatologic conditions in patients infected with HIV. J Am Acad Dermatol. 1997; 37:450-72. [IDIS 392270] [PubMed 9308562]



109. Peterson CM, Eichenfield LF. Scabies. Ped Annals. 1996; 25:97-100.



110. Kerl H, Ackerman AB. Inflammatory diseases that simulate lymphomas: cutaneous pseudolymphomas. In: Fitzpatrick TB, Eisen AZ, Wolff K et al, eds. Dermatology in general medicine. 4th ed. New York: McGraw Hill Inc. 1993:1315-27.



111. Wilson DC, Leyva WH, King LE. Arthropod bites and stings. In: Fitzpatrick TB, Eisen AZ, Wolff K et al, eds. Dermatology in general medicine. 4th ed. New York: McGraw Hill Inc. 1993:2810-26.



112. Degelau J. Scabies in long-term care facilities. Infect Control Hosp Epidemiol. 1992; 13:421-5. [PubMed 1640101]



113. Kolar KA, Rapini RP. Crusted (Norwegian) scabies. Am Fam Physician. 1991; 44:1317-21. [PubMed 1718155]



114. Lindane Lotion USP, 1% prescribing information. From the FDA web site (). Accessed 2003 Apr 4.



115. Westwood-Squibb Pharmaceuticals Inc. Eurax (crotamiton) lotion/cream prescribing information. Princeton, NJ; 2005 Jan.



116. Food and Drug Administration. FDA public health advisory: safety of topical lindane products for the treatment of scabies and lice. 2003 Mar 28. From FDA website (). Accessed March 29, 2007.



a. AHFS Drug Information 2007. McEvoy GK, ed. Crotamiton. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3498-99.



117. Dika E, Tosti A, Goldovsky M et al. Percutaneous absorption of crotamiton in man following single and multiple dosing. Cutan Ocul Toxicol. 2006; 25:211-6. [PubMed 16980246]



118. Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Ped Dermatol. 1990; 7:67-73.



119. Scheinfeld N. Controlling scabies in institutional settins. A review of medications, treatment models, and implementation. Am J Dermatol. 2004; 5:31-7.



120. Hengge UR, Currie BJ, Jager G et al. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006; 6:769-79. [PubMed 17123897]



121. Amer M, El-Gharib I. Permethrin versus crotamiton and lindane in the treatment of scabies. Int J Dermatol. 1992; 31:357-8. [PubMed 1375206]



122. Walker GJA, Johnstone PW. Interventions for treating scabies . Cochrane Database Syst Rev. 2000;(3):CD000320.



More Eurax resources


  • Eurax Side Effects (in more detail)
  • Eurax Use in Pregnancy & Breastfeeding
  • Eurax Support Group
  • 0 Reviews for Eurax - Add your own review/rating


  • Eurax Prescribing Information (FDA)

  • Eurax Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Eurax Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Eurax Consumer Overview



Compare Eurax with other medications


  • Pruritus
  • Scabies

Posted by at No comments:
Labels:

Minoxidil topical



Class: Skin and Mucous Membrane Agents, Miscellaneous
ATC Class: C02DC01
VA Class: DE900
Chemical Name: 3-oxide 6-(1-piperidinyl)-2,4-pyrimidinediamine
Molecular Formula: C9H15N5O
CAS Number: 38304-91-5
Brands: Hair Regrowth, Rogaine, Theroxidil

Introduction

Hair stimulant; a piperidinopyrimidine-derivative vasodilator.5 19 20 37 43 44 73 4 9 14 15 20 40 43 56


Uses for Minoxidil


Androgenetic Alopecia


Stimulates regrowth of hair in men and women with androgenetic alopecia (male-pattern alopecia, hereditary alopecia, common male baldness).1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 85


Recommended for use in men who have general thinning of hair at the vertex of the scalp 115 116 121 122 123 126 and in women who have general thinning of hair in frontoparietal areas.115 117 May be ineffective in men or women with more extensive hair loss.116 117 121 122 123 126


Not recommended for patients without a family history of hair loss or for those with hair loss associated with childbirth, or for those who have hair loss that occurs suddenly or for unknown reasons.116 117 121 122 123 126


Generally most effective in men <40 years of age,5 115 116 100 101 with <10 years duration of hair loss,6 23 39 100 101 115 116 <10 cm diameter of baldness, 5 6 23 39 100 101 115 116 and with large number of terminal or intermediate hairs before initiation of therapy.5 23 39 100 101


Alopecia Areata


Has been used to promote hair regrowth in males and females with alopecia areata†, including alopecia totalis or universalis.9 44 45 46 47 48 49 50 51 52 53


Hair Transplantation


Has been used as an adjunct to hair transplantation†; may promote better evolution of hair grafts by reducing postoperative shedding of hair and hastening the onset of postsheddng hair regrowth.64 65


Minoxidil Dosage and Administration


Administration


Topical Administration


Apply topically to the scalp as a 2 or 5% solution or as a 5% foam.1 116 117 121 122 123 126 a b c d


For dermatologic use only;1 116 117 121 122 123 126 avoid contact with eyes, mucous membranes, or sensitive or abraded skin areas.1 40 85 101 (See Dermatologic Effects under Cautions.) If contact with any of these areas occurs, flush area with large amounts of cool water.1 85 116 117 121 122 123


Apply to the scalp only; do not apply to other areas of the body because of risk of systemic adverse effects.116 117 121 122 123 126 (See Systemic Effects under Cautions.)


In men, apply 2 or 5% solution or 5% foam to total affected (balding and anticipated balding) areas of the scalp twice daily, usually in the morning and evening.1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 101 116 117 121 122 123 126 c


In women, apply 2% solution to total affected areas of the scalp twice daily, usually in the morning and evening;117 d 5% solution and 5% foam should not be used in women.126 b c


Apply solution and foam to dry scalp.1 85 116 117 121 122 123 126 a b c d


To apply solution, use applicator provided by the manufacturer and apply evenly over total affected areas of the scalp.85 a b d


To apply foam, part hair into ≥1 rows to expose scalp.c Rinse hands with cold water and dry thoroughly to minimize foam melting on warm skin.c Hold container upside down and press nozzle to dispense ½ capful of foam onto fingers; apply foam to affected areas and gently massage into scalp.c


Wash hands thoroughly after application using fingertips.1 116 117 121 122 123 126 a b c d


Dosage


Adults


Androgenetic Alopecia

Treatment in Men

Topical

Apply 1 mL of 2 or 5% solution to affected areas of the scalp twice daily.1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 101 116 117 121 122 123 126 a b


Apply ½ capful of 5% foam to affected areas of the scalp twice daily.c


≥4 months of use may be necessary before regrowth observed.1 5 6 7 67 101 116 117 121 122 123 126 a b c d Therapy must be continued indefinitely for maintenance of hair growth.1 6 7 9 24 40 67 83 100 101 109 115 116 121 122 123 126


Treatment in Women

Topical

Apply 1 mL of 2% solution to affected areas of the scalp twice daily.117 d


≥4 months of use may be necessary before regrowth observed.1 5 6 7 67 101 116 117 121 122 123 126 a b c d Therapy must be continued indefinitely for maintenance of hair growth.1 6 7 9 24 40 67 83 100 101 109 115 116 121 122 123 126


Alopecia Areata†

Topical

Apply 1 mL of 5% solution to affected areas of the scalp twice daily.45 46 49 52 53 100 101


Prescribing Limits


Adults


Androgenetic Alopecia

Treatment in Men

Topical

Maximum 2 mL of 2 or 5% solution daily.1 116 117 121 122 123 126 a b d


Maximum ½ capful of 5% foam per application.c


Treatment in Women

Topical

Maximum 2 mL of 2% solution daily.1 116 117 121 122 123 126 a d


Special Populations


No special population dosage recommendations at this time.a b c d


Cautions for Minoxidil


Contraindications



  • Known hypersensitivity to minoxidil or any ingredient in the formulation.1



Warnings/Precautions


General Precautions


Dermatologic Effects

Possible adverse local dermatologic effects (e.g., pruritus, dryness, scaling/flaking, local irritation or burning);1 5 8 9 15 16 22 23 26 27 29 30 32 40 46 56 83 85 96 may occur more frequently with the 5 than the 2% topical solution126 and may result from alcohol contained in formulation1 85 and the wearing of a wig or hairpiece.53 Local irritation usually is mild1 5 9 15 16 26 29 38 39 46 51 53 56 83 85 96 and rarely requires discontinuance of therapy.46 51 56


If irritation occurs, flush area with large amounts of cool water; contact clinician if irritation persists.1 85 116 117 121 122 123


Increased hair growth outside area of drug application (e.g., face, beard, eyebrows, ear, arm) reported; possibly due to inadvertent transfer of drug solution.1 5 22 32 46 50 51 52 83


Systemic Effects

Potential systemic adverse effects (e.g., weight gain, edema, tachycardia, hypotension),1 9 22 32 40 86 93 100 110 111 especially in individuals with propensity for greater percutaneous absorption or with increased sensitivity to the drug.1 9 93 101 Excessive doses, local abrasion or inflammation, or severe sunburn also may increase risk of systemic effects.1 101 116 117 121 122 123 a b d


Use not recommended on inflamed, erythematous, infected, irritated, or painful scalp.116 117 121 122 123 a b c d


Exposure to UV Light

Severe UV light-induced skin injury (e.g., severe sunburn) may enhance percutaneous absorption and increase risk of systemic effects.1 101 (See Systemic Effects under Cautions.)


Specific Populations


Pregnancy

Category C.e


Lactation

Distributed into milk after oral administration;72 115 however, not known whether topical minoxidil is distributed into milk.d AAP classifies minoxidil as compatible with breast-feeding.e


Pediatric Use

Safety and efficacy not established in children <18 years of age.1


Women

Prior to initiating therapy for androgenetic alopecia, consider possibility of an underlying endocrine abnormality (e.g., polycystic ovary [Stein-Leventhal] syndrome, Cushing’s syndrome, androgen-secreting tumors, hypothyroidism).9 84 100 101


Severe, diffuse hypertrichosis involving the face and limbs reported in women after 2–3 months of therapy with 5% solution for treatment of androgenetic alopecia; resolved within 4–5 months following discontinuance of therapy.132


Common Adverse Effects


Pruritus, 1 5 8 9 15 16 22 23 26 27 29 30 32 40 46 56 83 85 96 dryness, 5 22 40 83 scaling/flaking, 1 5 9 26 46 83 local irritation or burning.1 5 9 15 16 26 29 38 39 46 51 53 56 83 85 96


Interactions for Minoxidil


Topical Preparations


Possible pharmacokinetic interaction (increased percutaneous absorption of minoxidil).101 129 130 Safety and efficacy of combined therapy with other topical drugs not established.131 Concomitant use with other topical drugs on the scalp is not recommended.a b c d


Specific Drugs












Drug



Interaction



Comments



Hypotensive agents (guanethidine)



Possible increased risk of orthostatic hypotension if systemic absorption of minoxidil occurs1



Use concomitantly with caution1



Tretinoin, topical



Potential increased percutaneous absorption of minoxidil101 129 130



Safety and efficacy of combined use requires further evaluation131


Minoxidil Pharmacokinetics


Absorption


Bioavailability


Minimally absorbed following topical application to intact scalp;1 15 16 43 61 1.4% of a 2% topical solution may be absorbed.70


Onset


Onset of hair regrowth is variable; however, 2 or ≥4 months usually required before evidence of regrowth is observed following topical administration with 2 or 5% topical solutions, respectively.1 23 25 27 30 34 36 59 101 116 117 121 122 123 126


Distribution


Extent


Not fully determined following topical administration;100 101 however, intact stratum corneum may serve as a barrier that inhibits substantial diffusion of topically applied minoxidil into systemic circulation.68 71 101


Not known whether topical minoxidil crosses the placenta or is distributed into milk.1 72 e


Elimination


Metabolism


Not fully determined following topical administration;1 however, appears to be converted in the hair follicle to an active metabolite, minoxidil sulfate, by minoxidil sulfotransferase.17


Elimination Route


Excreted principally in urine.61


Stability


Storage


Topical


Solution

20–25°C.126 132 Keep away from heat and flame.a b d


Foam

20–25°C.c Keep away from heat and flame; do not puncture or incinerate container.c


ActionsActions



  • Exact mechanism of action not fully elucidated; however, appears to act at the level of the hair follicle,4 5 6 7 9 10 14 15 16 17 18 19 20 31 62 81 possibly directly stimulating hair follicle epithelial growth.4 6 9 10 14 15 17 18 19 20 81 100




  • May induce follicle hypertrophy and a return to more normal hair follicle diameter and depth in existing small follicles (i.e., regrowth) rather than stimulation of new follicle formation.4 5 6 7 9 17 19 20 59




  • Appears to prolong the anagen phase of the hair follicle, and accelerate the cyclic turnover of vellus hair follicles, enabling these follicles to produce thick, terminal hair4 6 9 19 20 106




  • May directly induce proliferation of hair epithelial cells near the base of the hair follicle and increase incorporation of cysteine and glycine into the follicle;14 cysteine residues cross-link to form cystine, which provides strength to the hair shaft.59



Advice to Patients



  • Product is flammable; importance of keeping product and area of application away from open flame and heat.a b c d




  • Importance of using only as directed, only for the indicated types of hair loss, and for at least 2–4 months in order to see results; continuous use required to maintain hair regrowth.a b c d (See Topical Administration under Dosage and Administration.)




  • Importance of applying only to healthy, normal scalp and not using topical minoxidil if scalp is inflamed, erythematous, infected, irritated, or painful.116 117 121 122 123 Importance of avoiding contact with the eyes.a b c d




  • Importance of washing hands after application.a b c d




  • Importance of women using only 2% solution; 5% solution and 5% foam should not be used in women.a b c d




  • Importance of reporting any local or systemic adverse reactions, especially chest pain, tachycardia, dizziness, unexplained weight gain, or peripheral edema, to a clinician.a b c d




  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses.a b c d




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a b c d




  • Importance of informing patients of other important precautionary information.a b c d (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name






































Minoxidil

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Topical



Solution



2%*



Hair Regrowth (with alcohol 60% and propylene glycol)



Eckerd, Rite Aid



Rogaine Hair Regrowth Treatment for Men (with alcohol 60% and propylene glycol)



Pfizer



Rogaine Hair Regrowth Treatment for Women (with alcohol 60% and propylene glycol)



Pfizer



5%*



Rogaine for Men Extra Strength (with alcohol 30% and propylene glycol)



Pfizer



Theroxidil (with alcohol 30% and propylene glycol)



Harmony



Foam



5%*



Rogaine Hair Regrowth Treatment for Men (with alcohol SD 40-B, butane, butylated hydroxytoluene, isobutane, and propane)



Pfizer



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



1. The Upjohn Company. Rogaine (minoxidil topical solution) prescribing information. Kalamazoo, MI; 1990 Feb.



2. The Upjohn Company. Rogaine (minoxidil topical solution) product information. Kalamazoo, MI; 1988 Aug.



3. Dawber RPR. Aetiology and pathophysiology of hair loss. Dermatologica. 1987; 175(Suppl 2):23-8.



4. Headington JT. Hair follicle biology and topical minoxidil: possible mechanisms of action. Dermatologica. 1987; 175(Suppl 2):19-22. [PubMed 3319729]



5. Katz HI. Topical minoxidil: review of efficacy and safety. Cutis. 1989; 43:94-8. [PubMed 2644080]



6. Voorhees JJ. Editor’s summary. Dermatologica. 1987; 175(Suppl 2):54-6.



7. Katz HI. Topical minoxidil: review of efficacy. Clin Dermatol. 1988; 6:195-9. [PubMed 3063371]



8. Shupack JL, Kassimir JJ, Thirumoorthy T et al. Dose-response study of topical minoxidil in male pattern alopecia. J Am Acad Dermatol. 1987; 16:673-6. [PubMed 3549801]



9. Clissold SP, Heel RC. Topical minoxidil: preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs. 1987; 33:107-22. [IDIS 228948] [PubMed 3552591]



10. Fiedler-Weiss VC. Potential mechanisms of minoxidil-induced hair growth in alopecia areata. J Am Acad Dermatol. 1987; 16:653-6. [PubMed 3558910]



11. Bunker CB, Dowd PM. Topical minoxidil, scalp hair, and vasodilatation. Lancet. 1987; 1:1266.



12. Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol. 1987; 117:668-9. [IDIS 237238] [PubMed 3689690]



13. Fiedler-Weiss VC, Buys CM. Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. Br J Dermatol. 1987; 117:759- 63. [PubMed 3501310]



14. Buhl AE, Waldon DJ, Kawabe TT et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989; 92:315-20. [PubMed 2465357]



15. Fiedler VC. Minoxidil: clinical and basic research in perspective. Semin Dermatol. 1987; 6:101- 7.



16. Fiedler-Weiss VC. Minoxidil. Dermatol Clin. 1987; 5:627-35. [PubMed 3301118]



17. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol. 1987; 16:657-68. [PubMed 3558911]



18. Fiedler VC, Buys CM. Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. Dermatologica. 1987; 175(Suppl 2):29-35. [PubMed 2961630]



19. Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res Clin Exp. 1984; 36:1098-106.



20. Uno H, Cappas A, Schlagel C. Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques. Am J Dermatopathol. 1985; 7:283-97. [PubMed 4051135]



21. Eller MG, Szpunar GJ, Della-Coletta AA. Absorption of minoxidil after topical application: effect of frequency and site of application. Clin Pharmacol Ther. 1989; 45:396-402. [IDIS 253526] [PubMed 2702797]



22. Olsen EA, Weiner MS, Delong ER et al. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol. 1985; 13:185-92. [PubMed 3900155]



23. De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985; 121:197-202. [IDIS 196318] [PubMed 3883902]



24. Tosti A. Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. Dermatologica. 1986; 173:136-8. [PubMed 3770260]



25. Storer JS, Brzuskiewicz J, Floyd H et al. Review: topical minoxidil for male pattern baldness. Am J Med Sci. 1986; 291:328-33. [IDIS 215989] [PubMed 3518451]



26. Civatte J, Laux B, Simpson NB et al. 2% topical minoxidil solution in androgenetic baldness: preliminary European results. Dermatologica. 1987; 175(Suppl 2):42-9. [PubMed 3319731]



27. Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol. 1987; 16:677-85. [PubMed 3549802]



28. Kreindler TG. Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol. 1987; 16:718-24. [PubMed 3549807]



29. Roberts JL. Androgenetic alopecia: treatment results with topical minoxidil. J Am Acad Dermatol. 1987; 16:705-10. [PubMed 3549805]



30. Savin RC. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol. 1987; 16:696-704. [PubMed 3549804]



31. Katz HI, Hien NT, Prawer SE et al. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1987; 16:711-8. [PubMed 3549806]



32. Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol. 1987; 16:688-95. [PubMed 3549803]



33. Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1986; 15:30-7. [PubMed 3722507]



34. De Villez RL. Androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1987; 16:669-72. [PubMed 3549800]



35. De Villez RL. Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. Dermatologica. 1987; 175(Suppl 2):50-3.



36. Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. Arch Dermatol. 1987; 123:1483-7. [IDIS 235936] [PubMed 3314717]



37. Vanderveen EE, Ellis CN, Kang S et al. Topical minoxidil for hair regrowth. J Am Acad Dermatol. 1984; 11:416-21. [PubMed 6384289]



38. Weiss VC, West DP. Topical minoxidil therapy and hair regrowth. Arch Dermatol. 1985; 121:191-2. [IDIS 196316] [PubMed 3977331]



39. Rumsfield JA, West DP, Fiedler-Weiss VC. Topical minoxidil therapy for hair regrowth. Clin Pharm. 1987; 6:386-92. [IDIS 229037] [PubMed 3311578]



40. de Groot AC, Nater JP, Herxheimer A. Minoxidil: hope for the bald? Lancet. 1987; 1:1019-21. Editorial.



41. Mitchell AD, De Villez R. Minoxidil for male- pattern baldness. Lancet. 1987; 1:1436. [PubMed 2884528]



42. de Groot AC, Nater JP, Herxheimer A. Minoxidil for male-pattern baldness. Lancet. 1987; 2:563. [PubMed 2887848]



43. Novak E, Franz TJ, Headington JT et al. Topically applied minoxidil in baldness. Int J Dermatol. 1985; 24:82-7. [PubMed 3886571]



44. Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. BMJ. 1983; 287:1015-7. [IDIS 177632] [PubMed 6412929]



45. Weiss VC, West DP, Fu TS et al. Alopecia areata treated with topical minoxidil. Arch Dermatol. 1984; 120:457-63. [IDIS 185288] [PubMed 6703751]



46. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987; 16:730-6. [PubMed 3549809]



47. King CM, Harrop B, Dave VK. Topical minoxidil in the treatment of alopecia areata. BMJ. 1983; 287:1380. [IDIS 178404] [PubMed 6416428]



48. Maitland JM, Aldridge RD, Main RA et al. Topical minoxidil in the treatment of alopecia areata. BMJ. 1984; 288:794. [IDIS 183293] [PubMed 6423083]



49. Fiedler-Weiss VC, West DP, Buys CM et al. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol. 1986; 122:180-2. [IDIS 211658] [PubMed 3947124]



50. White SI, Friedmann PS. Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol. 1985; 121:591. [IDIS 199275] [PubMed 3994404]



51. Price VH. Topical minoxidil in extensive alopecia areata, including 3-year follow-up. Dermatologica. 1987; 175(Suppl 2):36-41. [PubMed 3691913]



52. Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol. 1987; 16:737-44. [PubMed 3549810]



53. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987; 16:745-8. [PubMed 3549811]



54. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann NY Acad Sci. 1951; 53:708- 28. [PubMed 14819896]



55. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975; 68:1359-65. [PubMed 1188424]



56. Roenigk HH Jr, Pepper E, Kuruvilla S. Topical minoxidil therapy for hereditary male pattern alopecia. Cutis. 1987; 39:337-42. [PubM

Posted by at No comments:
Labels:

Tarocort



Generic Name: hydrocortisone valerate (Topical application route)


hye-droe-KOR-ti-sone VAL-er-ate


Commonly used brand name(s)

In the U.S.


  • Westcort

In Canada


  • Hydroval

  • Tarocort

Available Dosage Forms:


  • Ointment

  • Cream

Therapeutic Class: Corticosteroid, Intermediate


Pharmacologic Class: Hydrocortisone


Uses For Tarocort


Hydrocortisone valerate topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid).


This medicine is available only with your doctor's prescription.


Before Using Tarocort


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of hydrocortisone valerate topical in the pediatric population. However, because of this medicine's toxicity, it should be used with caution. Children and teenagers who must use this medicine should be checked often by their doctor since hydrocortisone valerate topical may be absorbed through the skin and can affect growth or cause other unwanted effects. Safety and effectiveness have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of hydrocortisone valerate topical in the elderly.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Cushing's syndrome (adrenal gland disorder) or

  • Diabetes or

  • Hyperglycemia (high blood sugar) or

  • Intracranial hypertension (increased pressure in the head)—Use with caution. May make these conditions worse.

  • Infection at or near the place of application or

  • Large sores, broken skin, or severe injury at the area of application—The chance of side effects may be increased.

Proper Use of hydrocortisone valerate

This section provides information on the proper use of a number of products that contain hydrocortisone valerate. It may not be specific to Tarocort. Please read with care.


Use this medicine exactly as directed by your doctor. Do not use it for any other condition without first checking with your doctor. This medicine may cause unwanted effects if it is used too much, because more of it is absorbed into the body through the skin.


Wash your hands with soap and water before and after using this medicine.


Be very careful not to get this medicine in your eyes. Wash your hands after using your finger to apply the medicine. If you accidentally get this medicine in your eyes, flush them with water.


Apply a thin layer of this medicine to the affected area of the skin. Rub it in gently.


Unless otherwise directed by your doctor, do not apply this medicine to open wounds, burns, or broken or inflamed skin.


This medicine should only be used for problems being treated by your doctor. Check with your doctor before using it for other problems, especially if you think that an infection may be present. This medicine should not be used to treat certain kinds of skin infections or serious problems, such as severe burns.


Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.


If your doctor has ordered an occlusive dressing (airtight covering, such as kitchen plastic wrap or a special patch) to be applied over this medicine, make sure you know how to apply it. Since occlusive dressings increase the amount of medicine absorbed through your skin and the possibility of side effects, use them only as directed. If you have any questions about this, check with your doctor.


Do not use this medicine on the face, groin, or underarms unless directed to do so by your doctor.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For topical dosage forms (cream and ointment):
    • For redness, itching, and swelling of the skin:
      • Adults—Apply to the affected area of the skin two or three times a day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Tarocort


It is very important that your doctor check your or your child's progress at regular visits for any problems or unwanted effects that may be caused by this medicine.


If your symptoms do not improve within 2 weeks, or if it become worse, check with your doctor.


After applying this medicine to the skin of your child, watch the child carefully to make sure that he or she does not get any of the medicine in the eyes or mouth. This medicine can cause serious side effects, especially in children, if it gets into the mouth and is swallowed.


Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and for patients who use large amounts for a long time. Talk to your doctor if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.


Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.


Avoid using tight-fitting diapers or plastic pants on a child if this medicine is being used on the child's diaper area. Plastic pants and tight-fitting diapers may increase the chance of absorption of the medicine through the skin and the chance of side effects.


Do not use cosmetics or other skin care products on the treated skin areas.


Tarocort Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Skin rash, encrusted, scaly, and oozing

  • stinging

Less common
  • Burning, itching, redness, skin rash, swelling, or soreness at the application site

  • cough or hoarseness

  • dry skin

  • fever or chills

  • itching in the genital or other skin areas

  • lower back or side pain

  • painful or difficult urination

  • rash

  • rash with flat lesions or small raised lesions on the skin

  • skin irritation

Incidence not known
  • Blistering, burning, crusting, dryness, or flaking of the skin

  • itching, scaling, severe redness, soreness, or swelling of the skin

  • redness and scaling around the mouth

  • thinning of the skin with easy bruising, especially when used on facial or intertriginous areas

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Diarrhea

  • indigestion

  • loss of appetite

  • nausea or vomiting

  • passing of gas

  • stomach pain, fullness, or discomfort

Incidence not known
  • Acne or pimples

  • burning and itching of the skin with pinhead-sized red blisters

  • burning, itching, and pain in hairy areas, or pus at the root of the hair

  • increased hair growth on the forehead, back, arms, and legs

  • lightening of normal skin color

  • lightening of treated areas of dark skin

  • reddish purple lines on the arms, face, legs, trunk, or groin

  • softening of the skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Tarocort resources


  • Tarocort Use in Pregnancy & Breastfeeding
  • Tarocort Drug Interactions
  • Tarocort Support Group
  • 15 Reviews for Tarocort - Add your own review/rating


Compare Tarocort with other medications


  • Anal Itching
  • Aphthous Stomatitis, Recurrent
  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Gingivitis
  • Hemorrhoids
  • Proctitis
  • Pruritus
  • Psoriasis
  • Seborrheic Dermatitis
  • Skin Rash
  • Ulcerative Colitis, Active

Posted by at No comments:
Labels:

Monday, 7 May 2012

Sulfacetamide Sodium/Sulfur Cleanser


Pronunciation: SUL-fa-SEET-a-mide SOE-dee-um/SUL-fur
Generic Name: Sulfacetamide Sodium/Sulfur
Brand Name: Avar LS Cleanser


Sulfacetamide Sodium/Sulfur Cleanser is used for:

Treating acne, rosacea, and oily, flaky skin (seborrhea). It may also be used for other conditions as determined by your doctor.


Sulfacetamide Sodium/Sulfur Cleanser is a sulfonamide antibiotic and keratolytic combination. The sulfonamide works by killing bacteria and the keratolytic works by shedding the top layer of skin.


Do NOT use Sulfacetamide Sodium/Sulfur Cleanser if:


  • you are allergic to any ingredient in Sulfacetamide Sodium/Sulfur Cleanser

  • you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) to any other sulfonamide medicine, such as acetazolamide, celecoxib, certain diuretics (eg, hydrochlorothiazide), glyburide, probenecid, sulfamethoxazole, valdecoxib, or zonisamide

  • you have kidney disease

Contact your doctor or health care provider right away if any of these apply to you.



Before using Sulfacetamide Sodium/Sulfur Cleanser:


Some medical conditions may interact with Sulfacetamide Sodium/Sulfur Cleanser. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have eczema or a history of lupus

Some MEDICINES MAY INTERACT with Sulfacetamide Sodium/Sulfur Cleanser. Because little, if any, of Sulfacetamide Sodium/Sulfur Cleanser is absorbed into the blood, the risk of it interacting with another medicine is low.


Ask your health care provider if Sulfacetamide Sodium/Sulfur Cleanser may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Sulfacetamide Sodium/Sulfur Cleanser:


Use Sulfacetamide Sodium/Sulfur Cleanser as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Sulfacetamide Sodium/Sulfur Cleanser is for use on the skin only. Sulfacetamide Sodium/Sulfur Cleanser may stain clothing and the skin if too much is used.

  • Wash your hands before and immediately after using Sulfacetamide Sodium/Sulfur Cleanser.

  • Wet the skin and apply a generous amount of medicine to the affected area. Massage gently into the skin for 10 to 20 seconds, working into a full lather. Rinse well and pat dry.

  • If the affected area becomes excessively dry, check with your doctor. You may need to rinse the medicine off the skin sooner or use it less often.

  • Sulfacetamide Sodium/Sulfur Cleanser works best if it is used at the same time(s) each day.

  • Continue to use Sulfacetamide Sodium/Sulfur Cleanser even if your condition improves. Do not miss any doses.

  • If you miss a dose of Sulfacetamide Sodium/Sulfur Cleanser, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Sulfacetamide Sodium/Sulfur Cleanser.



Important safety information:


  • Sulfacetamide Sodium/Sulfur Cleanser is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in any of these areas, rinse right away with cool tap water.

  • Talk with your doctor before you use any other medicines or cleansers on your skin.

  • Do not apply Sulfacetamide Sodium/Sulfur Cleanser to open wounds or to damaged or burned skin without first checking with your doctor.

  • If you use topical products too often, your condition may become worse.

  • Sulfacetamide Sodium/Sulfur Cleanser should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Sulfacetamide Sodium/Sulfur Cleanser while you are pregnant. It is not known if Sulfacetamide Sodium/Sulfur Cleanser is found in breast milk after topical use. If you are or will be breast-feeding while you use Sulfacetamide Sodium/Sulfur Cleanser, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Sulfacetamide Sodium/Sulfur Cleanser:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Mild dryness, redness, scaling, stinging, or burning of the skin.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); butterfly-shaped rash on the face; cracked or extremely dry skin; fever, chills, or sore throat; joint pain; red, swollen, blistered, or peeling skin; seizures; severe skin redness or scaling; skin inflammation or irritation; unusual tiredness or weakness; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Sulfacetamide Sodium/Sulfur side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Sulfacetamide Sodium/Sulfur Cleanser may be harmful if swallowed. Symptoms of ingestion may include change in the amount of urine; nausea; vomiting.


Proper storage of Sulfacetamide Sodium/Sulfur Cleanser:

Store Sulfacetamide Sodium/Sulfur Cleanser at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Keep the container tightly closed. Store away from heat and light. Do not freeze. Keep Sulfacetamide Sodium/Sulfur Cleanser out of the reach of children and away from pets.


General information:


  • If you have any questions about Sulfacetamide Sodium/Sulfur Cleanser, please talk with your doctor, pharmacist, or other health care provider.

  • Sulfacetamide Sodium/Sulfur Cleanser is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Sulfacetamide Sodium/Sulfur Cleanser. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Sulfacetamide Sodium/Sulfur resources


  • Sulfacetamide Sodium/Sulfur Side Effects (in more detail)
  • Sulfacetamide Sodium/Sulfur Use in Pregnancy & Breastfeeding
  • Sulfacetamide Sodium/Sulfur Drug Interactions
  • Sulfacetamide Sodium/Sulfur Support Group
  • 18 Reviews for Sulfacetamide Sodium/Sulfur - Add your own review/rating


Compare Sulfacetamide Sodium/Sulfur with other medications


  • Acne
  • Rosacea
  • Seborrheic Dermatitis

Posted by at No comments:
Labels:

Saturday, 5 May 2012

Imin




Imin may be available in the countries listed below.


Ingredient matches for Imin



Inosine Pranobex

Inosine Pranobex is reported as an ingredient of Imin in the following countries:


  • Singapore

International Drug Name Search

Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)